12.09.2024
                Advances With Various Therapies Targeting DLL3 in Lung Neuroendocrine Tumors
                ...Martin Wermke, MD from TU Dresden NCT/UCC Early Clinical Trial Unit Dresden in Germany, led the presentation, discussing results from a phase 1 trial of rovalpituzumab tesirine (Rova-T), which was the first DLL3 target agent to be explored in small cell lung cancer (SCLC)....
                Quelle: pharmacytimes.com